ARTICLE | Emerging Company Profile
Aspen plans to drive iPS cell therapy into Parkinson’s patients with $70M A round
Aspen is navigating a path to the clinic through the COVID-19 crisis with its OrbiMed-led venture round
April 1, 2020 12:32 PM UTC
Updated on Apr 2, 2020 at 1:33 AM UTC
Aspen plans to bring its autologous iPS cell-based therapy into Parkinson’s disease patients while exploring the stem cell platform in new indications with a $70 million series A round led by OrbiMed Advisors.
Existing investors Arch Venture Partners, Domain Associates and Section 32 and new investors Frazier Healthcare Partners and Sam Altman also participated in the round announced on Wednesday. ...